Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade

Cell Cycle

Volumn 11, Issue 18, 2012, Pages 3373-3379

  Fujii, Makiko ^a   Nakanishi, Hayao ^a   Toyoda, Takeshi ^b   Tanaka, Ichidai ^a,c   Kondo, Yutaka ^a   Osada, Hirotaka ^a,c   Sekido, Yoshitaka ^a,c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CTGF; Hippo pathway; Malignant mesothelioma; Mesothelial cells; p300; Smad; Targeted therapy; TEAD; TGF ; YAP

Indexed keywords

ANTINEOPLASTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; NEUROFIBROMATOSIS 2 PROTEIN; PEPTIDES AND PROTEINS; SHORT HAIRPIN RNA; SMAD PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

CANCER CELL; CANCER PATIENT; EXTRACELLULAR MATRIX; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA; HIPPO SIGNALING; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MESOTHELIUM CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84866747307     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21397     Document Type: Review

References (53)

1. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology 2002; 7:171-91; PMID:12153683; http://dx.doi.org/10. 1046/j.1440-1843.2002.00404.x.
2. Whitaker D, Papadimitriou J. Mesothelial healing: morphological and kinetic investigations. J Pathol 1985; 145:159-75; PMID:3973769; http://dx.doi.org/10.1002/path.1711450204.
3. Fotev Z, Whitaker D, Papadimitriou JM. Role of macrophages in mesothelial healing. J Pathol 1987; 151:209-19; PMID:3572615; http://dx.doi.org/10.1002/ path.1711510309.
4. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29:5-17; PMID:9076937; http://dx.doi.org/10.1016/S1357-2725(96)00115-X.
5. Herrick SE, Mutsaers SE. Mesothelial progenitor cells and their potential in tissue engineering. Int J Biochem Cell Biol 2004; 36:621-42; PMID:15010328; http://dx.doi.org/10.1016/j.biocel.2003.11.002.
6. de Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A 1978; 75:4001-5; PMID:211512; http://dx.doi.org/10.1073/pnas.75.8.4001.
7. Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A 1983; 80:6264-8; PMID:6604914; http://dx.doi.org/10.1073/pnas.80.20.6264.
8. Moses HL, Branum EL, Proper JA, Robinson RA. Transforming growth factor production by chemically transformed cells. Cancer Res 1981; 41:2842-8; PMID:6265069.
9. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003; 100:8621-3; PMID:12861075; http://dx.doi.org/10.1073/pnas.1633291100.
10. Massagué J. TGFbeta in Cancer. Cell 2008; 134:215-30; PMID:18662538; http://dx.doi.org/10.1016/j.cell.2008.07.001.
11. Shi Y, Massagué J. Mechanisms of TGFbeta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700; PMID:12809600; http://dx.doi.org/10.1016/S0092-8674(03)00432-X.
12. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, et al. TGFβ synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 2012; 209:479-94; PMID:22329991; http://dx.doi.org/10.1084/jem.20111653.
13. Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 1989; 134:979-91; PMID:2541616.
14. Gabrielson EW, Gerwin BI, Harris CC, Roberts AB, Sporn MB, Lechner JF. Stimulation of DNA synthesis in cultured primary human mesothelial cells by specific growth factors. FASEB J 1988; 2:2717-21; PMID:3260881.
15. Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, et al. Transforming growth factor-beta 1 (TGFbeta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 1994; 98:319-22; PMID:7955539; http://dx.doi.org/10. 1111/j.1365-2249.1994.tb06144.x.
16. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, et al. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10:5907-18; PMID:15355924; http://dx.doi.org/10. 1158/1078-0432.CCR-03-0611.
17. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67:2351-9; PMID:17332368; http://dx.doi.org/10.1158/0008-5472.CAN-06-2389.
18. Creasy CL, Chernoff J. Cloning and characterization of a human protein kinase with homology to Ste20. J Biol Chem 1995; 270:21695-700; PMID:7665586; http://dx.doi.org/10.1074/jbc.270.37.21695.
19. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011.
20. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13:877-83; PMID:21808241; http://dx.doi.org/10.1038/ncb2303.
21. Bao Y, Hata Y, Ikeda M, Withanage K. Mammalian Hippo pathway: from development to cancer and beyond. J Biochem 2011; 149:361-79; PMID:21324984; http://dx.doi.org/10.1093/jb/mvr021.
22. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22:1962-71; PMID:18579750; http://dx.doi.org/10.1101/gad.1664408.
23. Fernandez-L A, Kenney AM. The Hippo in the room: a new look at a key pathway in cell growth and transformation. Cell Cycle 2010; 9:2292-9; PMID:20581446; http://dx.doi.org/10.4161/cc.9.12.11919.
24. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15:1229-41; PMID:11358867; http://dx.doi.org/10.1101/gad.888601.
25. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007; 98:438-46; PMID:17270034; http://dx.doi.org/10.1111/j.1349-7006.2006.00386.x.
26. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006; 24:5223-33; PMID:17114655; http://dx.doi.org/10.1200/JCO.2006.06.3701.
27. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67; PMID:16814713; http://dx.doi.org/10.1016/j.cell.2006.05.030.
28. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32:389-98; PMID:21112960; http://dx.doi.org/10.1093/carcin/bgq254.
29. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012; 11:1090-6; PMID:22356765; http://dx.doi.org/10.4161/cc.11.6.19453.
30. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39:1582-9; PMID:18703216; http://dx.doi.org/10.1016/j.humpath.2008.04.012.
31. Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan KH, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One 2011; 6:e27529; PMID:22096589; http://dx.doi.org/10.1371/journal.pone. 0027529.
32. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130:1120-33; PMID:17889654; http://dx.doi.org/10.1016/j.cell.2007.07. 019.
33. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995; 92:10854-8; PMID:7479897; http://dx.doi.org/10.1073/pnas.92.24.10854.
34. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55:1227-31; PMID:7882313.
35. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011; 19:527-40; PMID:21481793; http://dx.doi.org/10.1016/j.ccr.2011.02.017.
36. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011; 71:873-83; PMID:21245096; http://dx.doi.org/10.1158/0008-5472.CAN-10-2164.
37. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 2009; 69:775-84; PMID:19179545; http://dx.doi.org/10.1158/0008-5472.CAN-08-0987.
38. Zhao B, Kim J, Ye X, Lai ZC, Guan KL. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res 2009; 69:1089-98; PMID:19141641; http://dx.doi.org/10.1158/0008-5472.CAN-08-2997.
39. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10:837-48; PMID:18568018; http://dx.doi.org/10.1038/ncb1748.
40. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGFβ-SMAD pathway. Dev Cell 2010; 19:831-44; PMID:21145499; http://dx.doi.org/10.1016/j.devcel.2010.11.012.
41. Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGFbeta pathways. Cell 2009; 139:757-69; PMID:19914168; http://dx.doi.org/10. 1016/j.cell.2009.09.035.
42. Fujii M, Lyakh LA, Bracken CP, Fukuoka J, Hayakawa M, Tsukiyama T, et al. SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes. Mol Cell 2006; 24:771-83; PMID:17157259; http://dx.doi.org/10.1016/j.molcel.2006.11.006.
43. Wu S, Liu Y, Zheng Y, Dong J, Pan D. The TEAD/ TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 2008; 14:388-98; PMID:18258486; http://dx.doi.org/10.1016/j. devcel.2008.01.007.
44. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284:13355-62; PMID:19324877; http://dx.doi.org/10. 1074/jbc.M900843200.
45. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248:44-57; PMID:10094812; http://dx.doi.org/10. 1006/excr.1999.4456.
46. Oemar BS, Lüscher TF. Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol 1997; 17:1483-9; PMID:9301624; http://dx.doi.org/10.1161/01.ATV.17.8.1483.
47. Nakanishi T, Kimura Y, Tamura T, Ichikawa H, Yamaai Y, Sugimoto T, et al. Cloning of a mRNA preferentially expressed in chondrocytes by differential display-PCR from a human chondrocytic cell line that is identical with connective tissue growth factor (CTGF) mRNA. Biochem Biophys Res Commun 1997; 234:206-10; PMID:9168990; http://dx.doi.org/10.1006/bbrc.1997.6528.
48. Surveyor GA, Wilson AK, Brigstock DR. Localization of connective tissue growth factor during the period of embryo implantation in the mouse. Biol Reprod 1998; 59:1207-13; PMID:9780329; http://dx.doi.org/10.1095/biolreprod59.5.1207.
49. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, et al. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012; 11:2272-84; PMID:22684333; http://dx.doi.org/10.4161/cc.20717.
50. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 2006; 104:e129-34; PMID:16902316; http://dx.doi.org/10.1159/000094963.
51. Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M, et al. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem 2011; 150:199-208; PMID:21586534; http://dx.doi.org/10.1093/jb/mvr063.
52. Kawaki H, Kubota S, Suzuki A, Suzuki M, Kohsaka K, Hoshi K, et al. Differential roles of CCN family proteins during osteoblast differentiation: Involvement of Smad and MAPK signaling pathways. Bone 2011; 49:975-89; PMID:21763478; http://dx.doi.org/10.1016/j.bone.2011.06.033.
53. Shi-wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000; 259:213-24; PMID:10942593; http://dx.doi.org/10.1006/excr.2000.4972.